Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial

Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial

Abstract Background Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, approximately 25% of patients relapsed within 1 year after surgery, indica...

Full description

Bibliographic Details
Main Authors: Guozhen Yang, Xiaodong Su, Yuanheng Huang, Guangyu Luo, Zhiqiang Wang, Peiqiang Cai, Yating Zheng, Ting Bei, Mengli Huang, Yuezong Bai, Haoqiang He, Jin Xiang, Muyan Cai, Jiudi Zhong, Qiyu Guo, Xu Zhang
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Journal of Translational Medicine
Subjects:
Neoadjuvant
Immunotherapy
Chemotherapy
ESCC
Online Access:https://doi.org/10.1186/s12967-023-04273-6

Internet

https://doi.org/10.1186/s12967-023-04273-6

Similar Items